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Highlight Box 5 
1. What is already known about this topic? 6 
Information on the economic impact of allergic rhinitis on work productivity remains 7 
fragmented and therefore cannot be taken efficiently into account by the medical 8 
community and policy makers. 9 
2. What does this article add to our knowledge? 10 
This systematic review confirms that rhinitis impacts at-work productivity more than 11 
absenteeism and provides a summary estimate that may serve as guidance for 12 
physicians and public health interventions.  13 
3. How does this study impact current management guidelines? 14 
Physicians should draw more attention to the burden of allergic rhinitis on work 15 
productivity, and inform the patient of the possible occupational impacts of the condition 16 
and the benefits of treatment. 17 
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Abstract 1 
Background: Allergic rhinitis (AR) is increasingly acknowledged as having a substantial 2 
socio-economic impact associated with impaired work productivity, although available 3 
information remains fragmented. 4 
Objective: This systematic review summarizes recently available information to provide a 5 
quantitative estimate of the burden of AR on work productivity including lost work time (i.e. 6 
absenteeism) and reduced performance while working (i.e. presenteeism) 7 
Methods: A Medline search retrieved original studies from 2005 to 2015 pertaining to the 8 
impact of AR on work productivity. A pooled analysis of results was carried out with studies 9 
reporting data collected through the validated Work Productivity and Activity Impairment 10 
(WPAI) questionnaire.  11 
Results: The search identified 19 observational surveys and 9 interventional studies. Six 12 
studies reported economic evaluations. Pooled analysis of WPAI-based studies found an 13 
estimated 2.3% (95% CI, 0; 7.9%) missed work time and 32.5% (95% CI, 20.8; 44.1%) 14 
impairment in at-work performance due to AR. Economic evaluations indicated that indirect 15 
costs associated with lost work productivity are the principal contributor to the total AR costs 16 
and result mainly from impaired presenteeism. The severity of AR symptoms was the most 17 
consistent disease-related factor associated with a greater impact of AR on work productivity, 18 
although ocular symptoms and sleep disturbances may independently affect work 19 
productivity. Overall, pharmacologic treatment of AR showed a beneficial effect on work 20 
productivity.  21 
Conclusions: This systematic review provides summary estimates of the magnitude of work 22 
productivity impairment due to AR and identifies its main determinant factors. This 23 
information may help guide both clinicians and health policy makers.  24 
Abstract word count: 249 words 25 
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INTRODUCTION 1 
Allergic rhinitis (AR) is a global public health issue due to its high prevalence and its adverse 2 
impacts on sleep, cognitive functioning, mood, and associated comorbid conditions, such as 3 
asthma and sinusitis, and ultimately on quality of life and work and school performance (1-3).  4 
A number of reviews have highlighted the socioeconomic burden of AR in terms of impaired 5 
work productivity, including lost work time (i.e. absenteeism) and reduced performance while 6 
working (i.e. impaired presenteeism) (4-8). Blanc et al. (9) first reported that reduction in self-7 
rated job effectiveness was more common in individuals with rhinitis (36%) than among those 8 
with asthma (19%) while absenteeism was similar in both conditions. US population-based 9 
surveys have provided estimates of the annual number of workdays missed because of AR 10 
ranging from 0.03 to 0.8 per employed individual (10-13). Goetzel et al. (14) combined data 11 
on work productivity impairment from three large-scale US surveys and concluded that 12 
‘allergy’ (excluding asthma) was associated with an average 3.4% (range: 0.3%-9.0%) 13 
productivity loss due to work absence and an average 10.9% (range: 8.3%-14.5%) reduction 14 
in at-work performance. Even though an increasing number of studies of AR have included 15 
quantitative and validated measures of absenteeism and presenteeism (15), to our 16 
knowledge, no systematic review (SR) of this area has yet been conducted. Therefore, 17 
available information on the impact of AR on work productivity remains fragmented and 18 
cannot be efficiently taken into account to guide clinical practice and public health 19 
interventions. 20 
This SR aimed to synthesize and critically analyze the available information pertaining to the 21 
burden of AR on work productivity both in terms of absenteeism and impaired presenteeism 22 
in order to derive summary quantitative estimates of these effects. The secondary aim of this 23 
SR was to identify the factors that may affect, either negatively or positively, these 24 
productivity impairments.  25 
METHODS 26 
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Protocol 1 
This SR was conducted according to the Preferred Reporting Items for Systematic reviews 2 
and Meta-Analyses (PRISMA) (www.prisma-statement.org) (16).  3 
Eligibility criteria 4 
We screened all original studies with an English abstract containing information on work 5 
productivity and/or indirect costs of rhinitis and published between January 2005 and 6 
December 2015. Case-series, review articles, and model-based economic evaluations were 7 
excluded. We did not consider studies published before 2005 as they have already been 8 
reviewed previously (4). 9 
Information Sources and Search Strategy 10 
The online database PubMed was searched using the following keywords: work [and] 11 
productivity [and] rhinitis; WPAI [and] rhinitis; productivity [and] rhinitis; and costs [and] work 12 
[and] rhinitis. Other databases were not searched, but we used the alternative strategy of 13 
sending the list of retrieved publications to an international panel of 11 experts in the field of 14 
allergy from 10 countries (Online Repository Table E1) asking them if they were aware of any 15 
other relevant published or unpublished data. In addition, the publications cited in the 16 
reference lists of the retrieved studies as well as review articles were carefully scrutinized to 17 
ensure that no original published data had been missed in the original search. 18 
Selection of Studies 19 
The 41 retrieved papers were screened for eligibility by two independent reviewers (JB and 20 
OV) followed by full text evaluation of the 35 articles that met the initial inclusion criteria (see 21 
Online Repository Figure 1). Twelve studies were excluded due to methodological issues or 22 
missing data (Online Repository Table E2). This process left 23 remaining studies (17-39). 23 
The expert panel feed-back identified four additional studies that were included in the 24 
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analysis (40-43). Another three relevant publications were retrieved through the analysis of 1 
citations lists (44-46).  2 
Data Collection Process 3 
The data from the 30 included studies were extracted in a standardized manner and verified 4 
by two authors (OV and JB) using a list of predefined variables (Online Repository Table E3). 5 
Authors were contacted whenever possible to obtain additional information unavailable in the 6 
original publication (30, 36, 41, 43).  7 
Assessment of the Quality of Selected Studies 8 
The studies were classified into three categories: 1) observational surveys; 2) interventional 9 
studies; and 3) economic evaluations of the impact of AR on work productivity. Bias in the 10 
observational surveys was evaluated using the Newcastle-Ottawa Quality scale for 11 
assessing the quality of cohort studies in meta-analyses 12 
(www.ohri.ca/programs/clinical_epidemiology/oxford.htm). The risk of bias in randomized 13 
controlled trials (RCT) was assessed using the descriptive Cochrane Collaboration’s ‘Risk of 14 
bias’ tool (47).  15 
Data Analysis 16 
Data of studies using the Work Productivity and Activity Impairment (WPAI)-Allergy Specific 17 
(AS) instrument were pooled to estimate the magnitude of the work productivity impairment 18 
related to AR. The WPAI-AS was selected as the outcome measure for this pooled analysis 19 
because it has been extensively validated in a large variety of health disorders (15, 48, 49) 20 
(http://www.reillyassociates.net/WPAI_References.html) and was the most commonly used 21 
instrument in the retrieved studies. The WPAI instrument produces three outcome measures 22 
of work disability: 1) the work time missed due to a specific health condition (i.e. 23 
absenteeism); 2) the productivity impairment while working due to the specific health 24 
condition (i.e., impaired presenteeism); and 3) the overall work impairment which is the sum 25 
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of absenteeism and impaired presenteeism (15, 48). These metrics are expressed as 1 
percentages (from 0% to 100%), with higher percentages indicating greater impairment. 2 
These were reported as non-integer summary values with a measure of variability for the 3 
distribution (e.g., a mean and standard deviation [SD] or a median and interquartile range) 4 
that varied among the studies.  5 
Baseline pre-intervention data that were reported separately by treatment vs. control group in 6 
RCTs contributed separately to the pooled estimate and, whenever possible, stratified data 7 
by the pattern of AR (i.e. seasonal/intermittent vs. persistent) or disease severity (mild vs. 8 
moderate-to-severe) also contributed separately to the overall pooled estimates. 9 
For each WPAI metric (absenteeism, presenteeism, and overall productivity impairment), the 10 
overall or subsets of pooled estimates of the mean value with its corresponding 95% 11 
confidence interval (95% CI) were calculated by weighting for the variance of each 12 
contributing value included in the estimate using a fixed effect approach. Since individual 13 
studies reported either standard error (SE), or standard deviation (SD) or interquartile range 14 
(IQR), the variance of each reported metric was derived by applying the following formulae 15 
as appropriate: V=n*SE², V=SD2 or V=(IQR/1.35)², assuming normal distributions. Pooling 16 
was not possible for absenteeism in persistent and mild AR because only a single 17 
study/stratum was applicable. We also excluded from the pooled analyses data for the 18 
stratum of observations for the placebo group in one interventional study (31) because it 19 
reported an extreme variance estimate that could not be verified. Pooled analyses were 20 
performed with arithmetic calculations of spreadsheet-entered data.  21 
A pooled analysis of the effects of treatment interventions on work productivity could not be 22 
conducted because data were not collected using the WPAI-AS (32) or were not 23 
appropriately reported (31, 33, 37-39). 24 
RESULTS 25 
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The 30 selected studies included 19 observational surveys (17-23, 25-30, 40, 41, 43-46) and 1 
9 interventional studies (31-39). Six studies reported economic evaluations (18, 24, 32, 41-2 
43), among which three were also identified among the observational surveys (18, 41, 43) 3 
and one among interventional studies (32).  4 
Characteristics of Observational Surveys 5 
The surveyed populations, diagnostic criteria and reported outcomes of the 19 observational 6 
surveys are summarized in Table 1 and Online Repository Table E4. The criteria and results 7 
of quality assessment are detailed in Online Repository Table E5. 8 
Populations 9 
The participants with AR were recruited from various population sources (Online Repository 10 
Table E4). Six studies compared AR individuals with referent groups without AR derived from 11 
the same population (18, 21, 22, 25, 44, 46), but adjustment for confounding demographic 12 
characteristics and multimobidity was performed in only two studies (25, 46).  13 
Characteristics of Allergic Rhinitis 14 
The diagnosis of AR was documented using various criteria as detailed in Online Repository 15 
Table E4. Ascertainment of allergen sensitization through skin-prick tests and/or serum 16 
specific IgE antibodies was used as a diagnostic criterion in only three surveys (25, 40, 43) 17 
and reported to be present in 41% to 55% of the AR participants in three other studies (17, 18 
19, 26). 19 
Five observational surveys provided the proportion of participants with moderate/severe AR 20 
(61% to 93%) (Table 1) (17, 21, 25, 30, 43). Work productivity was reported separately for 21 
mild and moderate/severe AR in only two studies (17, 43). Eleven studies reported the 22 
duration of AR symptoms (17, 22, 23, 26-30, 40, 43, 45). The proportion of persistent AR 23 
among these studies ranged from 0% to 72%. Data on work productivity were provided 24 
separately for persistent and intermittent AR in only two studies (17, 43). 25 
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Outcomes 1 
Seven surveys collected data on the impact of AR on work productivity using validated 2 
instruments (Table 1): the WPAI instrument either in its specific version for allergic diseases 3 
(WPAI-AS) (17, 19, 30, 43) or in its generic version (25), the Stanford Presenteeism Scale 4 
(SPS) (44), and the Work Productivity Short Inventory questionnaire (WPSI) (18). The recall 5 
periods assessed by these questionnaires were seven days, four weeks, and 12 months, 6 
respectively. In one prospective cohort study of AR participants recruited in a random sample 7 
of specialized clinics in Spain, the WPAI-AS questionnaire was administered quarterly over a 8 
one-year period (43). The remaining observational surveys collected information on the 9 
impact of AR on work productivity using diverse non-validated instruments. 10 
Characteristics of Interventional Studies 11 
Populations 12 
Eight of the nine interventional studies (Table 2 and Online Repository Table E6) were 13 
randomized controlled trials (RCTs) evaluating the effects of AR medications on work 14 
productivity (31-33, 35-39). One study was a pragmatic, investigator-randomized design and 15 
compared the treatment of AR based on the Allergic Rhinitis and its Impact on Asthma 16 
(ARIA) guidelines with a "free-choice” strategy (34). For two studies that failed to provide the 17 
number of enrolled participants who were currently employed, work and school productivity 18 
impairments could not be differentiated (35, 36). Quality assessment of interventional studies 19 
is presented in Online Repository Table E7. 20 
Characteristics of Allergic Rhinitis 21 
Sensitization to relevant allergens was ascertained in all AR participants, although the tested 22 
allergens were not detailed in four studies (33, 35, 36, 38). Five RCTs evaluated participants 23 
with “seasonal AR” (31, 33, 37, 39) and one RCT included participants with “intermittent AR” 24 
(35). Symptom severity at baseline was categorized according to a symptom score in six 25 
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RCTs and to the ARIA grades in one study (34), and was not specified in one study (33). The 1 
majority (n=7) of the nine RCTs enrolled participants with moderate-to-severe AR at baseline 2 
(Online Repository Table E6) (31, 32, 35-39).  3 
Outcomes 4 
The impact of AR on work productivity was assessed using the WPAI-AS questionnaire in 5 
eight RCTs (Table 2).  6 
Absenteeism 7 
Seven observational surveys reported that 3 to 30% of participants “missed work time due to 8 
AR” (22, 23, 26, 27, 29, 40, 45), but failed to provide any quantitative estimate of 9 
absenteeism (Table 1). Six observational surveys provided quantitative estimates of missed 10 
work time expressed as an absolute number of hours or days lost over variable intervals of 11 
time (Table 1) (18, 20, 21, 30, 41, 44). These estimates ranged from 0.8 to 9.9 workdays lost 12 
per year. The Medical Expenditure Panel Survey (MEPS) estimated a 0.6 incremental 13 
workday missed per year in participants with AR after controlling for socio-demographic 14 
characteristics, smoking, and multimorbidity (46). 15 
The pooled analysis of six WPAI-based studies (1,666 participants) provided an overall 16 
pooled estimate of 2.3% (95% CI, 0; 7.9%) missed work time due to AR (Table 3) (19, 25, 31, 17 
37, 39, 43).  18 
Presenteeism 19 
Seven observational surveys reported that 10% to 50% of participants with AR experienced 20 
“work limitation” related to AR (Table 2) (22, 23, 26-28, 30, 45). Seven observational surveys 21 
assessed quantitatively the impact of AR on work productivity using various non-validated 22 
indices (18, 23, 26, 27, 29, 30, 41) (Table 2). 23 
13 
 
The pooled analysis of impaired presenteeism included eight studies using the WPAI-AS 1 
instrument (4,563 participants) and provided an estimated 32.5% (95%CI, 20.8; 44.1%) 2 
impairment in work performance due to AR (Table 3) (17, 19, 25, 31, 34, 37, 39, 43). 3 
Overall Work Productivity  4 
The pooled analysis of 11 studies using the WPAI-AS questionnaire (6536 participants) 5 
found an estimated  35.5% (95% CI, 25.2; 45.8%) impairment in overall work productivity due 6 
to AR (Table 3) (17, 19, 25, 31, 33-37, 39, 43). 7 
Disease-Related Factors Impacting Work Productivity 8 
The severity of AR symptoms (17, 19, 21, 22, 25, 30, 41, 43) was the most consistent 9 
disease-related factor associated with a greater impact of AR on work productivity. The 10 
pooled analysis of WPAI questionnaire-based studies retrieved in this SR showed a trend 11 
toward greater impairment in overall work productivity impairment in moderate/severe AR 12 
(38.5% [95%CI, 27.0; 49.9]) as compared to mild AR (14.2% [95%CI, 0; 31.7]), although the 13 
difference was not significant (Table 3).  14 
Two studies reported that ocular symptoms (conjunctivitis) in addition to nasal symptoms 15 
were associated with a more detrimental effect on work productivity (20) or ‘professional 16 
effectiveness’ (22). One of these studies also documented an independent adverse effect of 17 
sleep disturbance and low health-related quality of life on work productivity (20).  18 
Impact of Pharmacologic Treatment 19 
Overall, RCTs reported a beneficial effect of the pharmacologic treatment of AR on work 20 
productivity (31-39) (Table 4). One study showed that treatment based on ARIA guidelines 21 
significantly improved absenteeism and presenteeism as compared with a “free-choice” 22 
treatment (34). 23 
Comparison with Other Health Conditions 24 
14 
 
A formal comparison of the work impairment due to AR with other chronic diseases could not 1 
be performed because the SR identified only three relevant surveys that used different 2 
outcome measures. Using the Stanford Presenteeism Scale, Collins et al. (44) found that the 3 
mean work time missed (0.9 hour [95% CI: 0.7-1.1]) in the last four weeks and work 4 
performance impairment (18.2% [95% CI: 17.5-18.8%]) related to AR were similar to those 5 
attributed to asthma, arthritis, diabetes, heart and circulatory problems, and musculoskeletal 6 
disorders. Lamb et al. (18) reported that the estimated mean total productivity loss per 7 
employee during the last year, including the number of days missed and the number of 8 
unproductive hours, was significantly higher for AR compared to ten other chronic conditions, 9 
including high stress, migraine, depression, arthritis/rheumatism, anxiety disorders, 10 
respiratory infections, hypertension, diabetes, asthma, and coronary heart disease. Using the 11 
generic WPAI, de la Hoz et al. (25) found that absenteeism was similar in AR (adjusted mean 12 
± SE, 4.6±1.1%) compared to diabetes (4.2±1.7%) and hypertension (2.1±1.5%) but 13 
significantly lower than in symptomatic depression (31.7±2.6%). AR was associated with a 14 
significantly higher overall loss of productivity (adjusted mean ± SE, 26.6±1.8%) than 15 
hypertension (8.8±2.5%) and diabetes (16.7±2.8%) but it was lower than in symptomatic 16 
depression (59.5±4.3%). 17 
Economic Evaluations 18 
Six studies assessed the economic costs of lost work productivity related to AR (Table 5) 19 
(18, 24, 32, 41-43). Overall, these economic evaluations indicated that the costs of impaired 20 
presenteeism were 2.2 to 18.7-fold higher than those of absenteeism, while the total costs of 21 
lost productivity (i.e. absenteeism plus impaired presenteeism) were 3.2 to 13.5-fold higher 22 
than the direct medical costs. The indirect costs resulting from lost work productivity 23 
represented 76% to 93% of the total AR costs.  24 
A Swedish population-based questionnaire survey (42) showed that the cost of moderate-to-25 
severe persistent AR was four-fold higher than mild persistent AR. A prospective 1-year 26 
15 
 
cohort study found that the mean indirect costs resulting from presenteeism were 1 
approximately 1.9-fold higher in moderate/severe AR compared to mild AR and 2.3-fold 2 
higher in participants with persistent AR compared to those with intermittent AR (43). The 3 
cost of absenteeism did not differ according to the severity or duration of AR symptoms. In 4 
persistent AR, the costs of absenteeism and presenteeism due to AR were significantly 5 
reduced in participants treated with levocetirizine as compared with placebo (32).  6 
DISCUSSION 7 
Summary of Evidence 8 
The pooled analysis of WPAI-based studies identified in this SR showed that AR is 9 
associated with a substantial adverse impact on the productivity at work (i.e. presenteeism) 10 
with an estimated 32.5% (95%CI, 20.8; 44.1%) impairment, while the impact on absenteeism 11 
was minimal (2.3% [95% CI, 0; 7.9%]). These figures are similar to previous estimates of 12 
absenteeism, while estimates of impaired productivity at work are higher than those reported 13 
in previous US surveys that used various instruments to quantify the impact of AR on work 14 
productivity (10-14). The estimates derived in this SR are however in line with those reported 15 
by two recently published WPAI-based studies conducted in Asian healthcare settings which 16 
documented mean (SD) overall productivity impairment due to AR of 32 (26)% and 40 (29)%) 17 
(50, 51). 18 
Overall, this SR indicated that the level of impaired productivity due to AR is at least similar 19 
to that reported in many other chronic diseases (18, 25, 44). The recent Asian studies cited 20 
previously further confirm that overall work productivity is more impaired by rhinitis than 21 
asthma (20 [25]% vs. 33 [30]%) and COPD (17 [27]% vs. 15 [23]%) (50, 51). In addition, our 22 
pooled estimate of the overall productivity impairment due to AR (35.5% [95% CI, 25.2; 23 
45.8%]) is in line with the mean (range) percentage impairment provided by a recent SR of 24 
WPAI-based studies in various chronic health disorders: depression (29%; 15-43%); chronic 25 
obstructive pulmonary disease (31%; 19-42%); irritable bowel syndrome and constipation 26 
16 
 
(36%; 21-51%); and arthritis (45%; 21-69%) (49). However, in this SR, the studies on asthma 1 
and “allergies” were pooled together and included only two studies on rhinitis (17, 48). 2 
Nevertheless, the impact of seasonal or intermittent AR is likely to be of more limited duration 3 
than other chronic diseases. 4 
This SR confirmed that more severe AR symptoms are associated with a more detrimental 5 
impact on work productivity (17, 19, 21, 22, 25, 30, 41, 43). These findings are further 6 
substantiated by a recent study showing a correlation between the WPAI-AS score and the 7 
overall intensity of AR symptoms assessed using a visual analogue scale (VAS) (52). In 8 
addition, this SR indicated that associated conjunctivitis and sleep disturbances could have 9 
detrimental effect on work productivity independently from nasal symptoms (20, 22). The 10 
aggravating role of ocular symptoms was further substantiated by an observational survey of 11 
AR patients recruited by primary care physicians and specialists which, however, was not 12 
eligible for inclusion in this SR because detailed WPAI questionnaire data were not reported 13 
(53). This study demonstrated that ocular symptoms were associated with a greater impact 14 
on absenteeism and productivity while at work, even after adjustment for the severity of nasal 15 
symptoms. A number of observational surveys in this SR reported on sleep problems related 16 
to AR (17, 19-21, 23, 26, 27, 40, 45), but they failed to investigate the specific impact of 17 
sleep disorders on work productivity, with the exception of the study by Szeinbach et al. (20). 18 
These findings – if further confirmed – may have clinical implications since ocular symptoms 19 
and sleep disturbances are highly prevalent among patients with AR and are often 20 
underestimated by health care providers (1, 54, 55). Greater awareness of these symptoms 21 
and their potential effects may help physicians to identify subjects with an increased risk of 22 
impaired work productivity and to target their treatment in order to reduce the work and 23 
economic impact of AR. 24 
Although a formal meta-analysis of the effects of pharmacological treatment of AR was not 25 
appropriate to the retrieved data, the RCTs identified through this SR showed an overall 26 
beneficial effect of oral antihistamines and nasal sprays on work productivity. These findings 27 
17 
 
are in line with a critical review of studies published before 2003 showing that treatment with 1 
non-sedating antihistamines reduces the productivity losses due to AR (56).  2 
Earlier population-based studies conducted in the US provided a wide range of estimates of 3 
the indirect costs of AR, ranging from 7% (11) to 25% (10) of the total costs. Unfortunately, 4 
few studies have assessed both absenteeism and presenteeism (6). The current SR 5 
indicates that: 1) the indirect costs associated with lost work productivity are the principal 6 
component of the total AR costs and result mainly from the costs of presenteeism and 2) the 7 
indirect costs of AR appear to be greater or similar to those resulting from many other 8 
chronic diseases traditionally considered as being more important from a medical 9 
perspective.  10 
Limitations 11 
Several methodological weaknesses of this SR should be considered for interpreting the 12 
estimates of the burden of AR on work productivity. First, the pooled estimates of the impact 13 
of AR on work productivity were derived from a limited number of studies based on the 14 
validated WPAI instrument. Most observational surveys used non-validated measures of at-15 
work productivity and most reports of the effects of pharmacological interventions presented 16 
data in a form that could not be utilized in a pooled analysis. The findings from these non-17 
WPAI studies were only descriptively assessed and summarized. Second, IgE sensitization 18 
to aeroallergens was not systematically documented in the majority of observational surveys. 19 
Thus, the findings derived from these surveys are likely to be relevant not only to AR, but 20 
also to other forms of rhinitis. 21 
Third, most available studies had a substantial, though unquantifiable, potential for bias 22 
toward the selection of participants with more severe AR. The AR subjects participating in 23 
population or patient panels (21-23, 26-30, 41) and ‘convenience’ samples surveys (18, 45) 24 
might be those who were more prone to report a higher impact of the disease. Individuals 25 
who seek primary healthcare (17, 19, 25, 40, 43) or managed care (20) are unlikely to 26 
18 
 
accurately represent the whole population of individuals suffering from AR. Only five of the 1 
19 observational surveys provided information on the severity of AR (17, 21, 25, 30, 43), and 2 
data on work productivity impairment associated with mild AR was available in only two 3 
studies (17, 43). Moderate-to-severe AR seemed to be over-represented in observational 4 
surveys as compared with existing population-based data (e.g. 29%-40% (54, 57)); the 5 
proportion of participants with moderate/severe AR ranged from 61% to 93% in the five 6 
surveys that provided this information (17, 21, 25, 30 , 43). In addition, RCTs are inherently 7 
affected by a selection bias toward more severe and/or symptomatic AR since, in these 8 
studies, only participants with a moderate to severe disease were enrolled.  9 
Studies based on self-reporting may be affected by recall failure and attribution bias (e.g. 10 
confusion about whether AR is the cause of the work impairment). Few available studies 11 
attempted to disentangle the impact of AR from that resulting from comorbid conditions, 12 
particularly asthma and rhinosinusitis, although these conditions may increase the adverse 13 
impact on work productivity (58, 59). Only two observational surveys took into account the 14 
potential confounding demographic characteristics and comorbidities in the analysis of their 15 
results (25, 46). 16 
A major limitation of our pooled analysis results from the fact that the impact of seasonal AR 17 
cannot be estimated on an annual time framework. The WPAI-AS questionnaire is one of the 18 
best validated tools to assess absenteeism and presenteeism in AR (15, 48). The WPAI-AS 19 
questionnaire is applied for a seven-day recall period in an attempt at minimizing the recall 20 
bias. However, most studies evaluating specifically individuals with seasonal AR were 21 
interventional studies based on the WPAI-AS which were conducted during the relevant 22 
pollen season and failed to provide information on the total duration of the symptomatic 23 
period (31, 33, 37, 39) while work impairment has been significantly correlated with outdoor 24 
pollen and mould levels in individuals with AR (60, 61). Apps running on smartphone devices 25 
can help gather real time information on daily work performance and AR symptoms over 26 
longer periods of time and, accordingly, should further reduce recall bias and make it 27 
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possible to estimate more accurately the cumulative impact of seasonal and intermittent AR 1 
on work productivity (62). 2 
Conclusion 3 
This SR indicates that AR is substantially impairing at-work productivity (presenteeism) but 4 
only minimally absenteeism, although further studies assessing daily work productivity and 5 
severity of symptoms at the same time over prolonged periods and comparing with other 6 
chronic diseases are needed to better characterize the impact of AR. Nevertheless, the 7 
findings of this SR should increase the awareness of the medical community on the impact of 8 
AR on work productivity and provide an evidence-base to assist healthcare payers and 9 
policy-makers implementing interventions to reduce the socioeconomic burden of AR. 10 
  11 
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Table 1. Observational surveys: Summary findings 
Reference Working AR adults 
Severity 
of AR 
Duration 
of AR 
Questionnaire 
instrument  Work time missed (absenteeism) Impairment in at-work productivity (presenteeism) 
Collins, 2005 (44) 1,472 NA NA SPS Mean (95% CI) missed work-time: 0.9 h (0.7-1.1) in 
the last 4 wk (estimate: 9.9 d/yr)¥  
Mean (95% CI) work impairment: 18.2 (17.5-18.8) 
Bousquet, 2006 (17) 84 Mild IAR WPAI-AS 0 Median (IQR) % work impairment: 20 (10-30) 
66 Mild PAR 0 Median (IQR) % work impairment: 20 (0-40) 
894 M/S IAR 0 Median (IQR) % work impairment: 40 (20-70) 
1,107 M/S PAR 0 Median (IQR) % work impairment: 40 (20-62) 
Lamb, 2006 (18) 4,524 NA NA WPSI Average missed work time: 3.6 d/yr Unproductive work due to AR: 2.3 h/d when 
experiencing Sx 
Stull, 2007 (19) 301 NA NA WPAI-AS Mean (SD) % missed work time: 6.8 (14.6) Mean (SD) % work impairment: 40.0 (26.9) 
Szeinbach, 2007 (20) 577 NA NA 10-point scale Average missed work time:1 h/wk (range: 0-32h) 
(estimate: 5.5 d/yr)¥ 
NA 
Valovirta, 2008 (45) 2,287 NA 
(AA: 42%) 
PAR: 62% Non-validated Taking time off work in the past yr  due to AR: 26% Work affected (unable to concentrate): average 49%  
Meltzer, 2009 (21) 3,831 M/S: 66% NA Non-validated • Mean (SD) entire workdays missed due to AR: 
0.4 (2.0) past 4 wk (estimate: 4.4 d/yr)* vs. 0.2 
(1.5) for non-AR (estimate: 2.2 d/yr)¥  
• Mean (SD) partial workdays missed due to AR: 
0.3 (1.9) past 4 wk vs. 0.1 (1.4) for non-AR 
NA 
Van Cauwenberge, 
2009 (22) 
600 NA SAR: 59% Non-validated Absence from work, late arrival or early departure: 
27%, average 6 h work missed per symptomatic wk  
Moderate or considerable effect of AR on 
concentration: 31% 
Neffen, 2010 (23) 1,088†  NA SAR: 62% Non-validated Missed work because of AR (past 12 mo): 20% Interference with work performance: 33%; 30% point 
decrease in work productivity related to AR  
de la Hoz, 2012 (25) 134 M/S: 61%* NA WPAI-Generic Adjusted mean (SE): 4.6 (1.1)%  Adjusted mean (SE): 23.5 (1.6)% 
Katelaris, 2011 (26) 1,043†  NA SAR: 66% Non-validated Missed work because of AR (past 12 mo): 25% Interference with work performance: 50%; 25% point 
decrease in work productivity related to AR 
Demoly, 2011 (40) 702† NA 
(AA: 22%)  
SAR: 51%  Non-validated Sick leave at the time of physician visit: 5.1% for an 
average of 4.5 days 
NA 
Bhattacharyya, 2012 
(46) 
NA NA NA Not detailed Mean (SE) incremental workdays lost/yr: 0.6 (0.4) 
vs. non-AR participants 
Proportion (SE) of participants with work limitation: 
13.9 (1.0)% vs. 10.4 (0.3) in non-AR participants; 
adjusted OR: 1.43 (95%CI: 1.2–1.7) 
Keith, 2012 (28) 1,001† NA 
(AA: 27%) 
SAR: 51% 3-point scale NA Reduced productivity during the allergy season: 2% 
very troublesome, 8% moderately troublesome 
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Meltzer, 2012 (27) 2,500†  NA 
(AA: 32%) 
PAR: 56% Non-validated Missed work because of AR during the past 12 mo: 
30% 
Interference with work performance : 42%; 23% point 
decrease in work productivity related to AR 
Bielory, 2014 (29) 962 NA SAR: 78% 100-point 
scale 
Missed work because of AR (unknown period of 
time assessed): 3% 
Reduced productivity by 26% points (from 91 to 65) 
when allergy Sx at their worst vs. no Sx 
Jantunen, 2014 (41) 636 NA NA 100-point 
scale 
Mean (SD) missed work time: 0.8 (5.1) days/yr Mean (SD) % reduction in work productivity: 15.2 
(14.5) % when Sx 
Price, 2015 (30) 691 M/S: 75% 
(AA: 30%) 
SAR: 
100% 
Categorical 
scale of 
impairment 
from 10% to 
100% 
Mean (SD) missed work time: 4.1 (16.4) days/yr in 
M/S AR vs. 2.5 (7.7) days/yr in mild AR 
• Decreased work performance >50% in 32.8% of 
M/S AR vs. 12.2% of mild AR 
• Decreased work performance on mean (SD) 37.7 
(53.0) days/yr in M/S AR vs. 21.0 (29.9) days/yr in 
mild AR. 
Colas, 2016 (43) 241 Mild Na WPAI-AS Mean (SD) % missed work time: 0.8 (1.6) (n=18) Mean (SD) % work impairment: 8.9 (11.7) (n=18) 
M/S Na Mean (SD) % missed work time: 1.9 (6.0) (n=223) Mean (SD) % work impairment: 16.9 (17.1) (n=199) 
Na IAR Mean (SD) % missed work time: 1.6 (4.4) (n=64) Mean (SD) % work impairment: 8.3 (8.8) (n=56) 
Na PAR Mean (SD) % missed work time: 1.9 (6.2) (n=177) Mean (SD) % work impairment: 19.0 (18.0) (n=161) 
Legend: AA: associated asthma; AR: allergic rhinitis; PAR = persistent AR; SAR = seasonal AR; M/S = moderate/severe AR; Sx: symptoms; SPS: Stanford Presenteeism Scale; WPAI-
AS: Work Productivity and Activity Impairment questionnaire-Allergy Specific; WPSI: Work Productivity Short Inventory 
* Severity assessed using the Clinical Global Impression (CGI) generic scale 
† Unknown working status 
¥ Estimate based on a 8-hour work day, 5 workdays per week and 220 workdays per year 
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Table 2. Interventional studies: Work productivity impairment at baseline assessment 
Reference Duration of AR 
Severity 
of AR Intervention group 
No. of 
participants 
% work time missed 
(absenteeism)* 
% impairment in at-work 
productivity 
(presenteeism)* 
% overall work 
impairment* 
Okubo, 2005 (31) SAR M/S Fexofenadine 79 Mean (SD): 1.1 (4.5) Mean (SD) : 39.1 (27.6) Mean (SD): 39.4 (27.9) 
Placebo 89 Mean (SD): 0.3 (1.7) Mean (SD): 36.6 (25.8) Mean (SD): 36.7 (25.9) 
Fairchild 2007 (33) SAR M/S Olopatadine NS 0.6% 293 NA NA Mean (SD) : 48.5 (24.7) 
Olopatadine NS 0.4%  303 NA NA Mean (SD): 45.0 (26.3) 
Placebo 297 NA NA Mean (SD): 44.1 (25.2) 
Bousquet, 2009 (34) PAR : 62% M/S : 72% ARIA guidelines 339 0 Median (IQR) : 30 (20-50) Median (IQR) : 30 (20-50) 
Free-choice 342 0 Median (IQR) : 30 (10-50) Median (IQR) : 30 (10-50) 
Bousquet, 2009 (35) IAR M/S Desloratadine 262† NA NA Mean (SEM): 46.4 (2.4) 
Placebo 256† NA NA Mean (SEM): 41.4 (2.3) 
Bousquet, 2010 (36) PAR M/S Desloratadine 301† NA NA Mean (SEM): 48.0 (2.4) 
Placebo 261† NA NA Mean (SEM) : 47.0 (2.3) 
Mansfield, 2010 (37) SAR M/S Levocetirizine 235 Mean (SD): 4.5 (12.9) Mean (SD): 51.8 (24.2) Mean (SD): 52.9 (24.9) 
Placebo 233 Mean (SD): 3.5 (9.8) Mean (SD): 49.0 (24.2) Mean (SD): 49.9 (24.6) 
Meltzer, 2010 (38) PAR M/S Mometasone NS 20 Mean (range): 4.7 (0-33.3) Mean (range): 5.9 (2.0-9.0) NA 
Placebo 9 Mean (range): 4.4 (0-20.0) Mean (range): 5.9 (3.0-9.0) NA 
Segall, 2010 (39) SAR M/S Levocetirizine 216 Mean (SD): 3.8 (11.2) Mean (SD) : 51.6 (24.1) Mean (SD): 52.5 (24.6) 
Placebo 227 Mean (SD): 3.3 (9.4) Mean (SD): 49.3 (24.0) Mean (SD): 50.1 (24.3) 
Legend: AR: allergic rhinitis; IAR = intermittent AR; PAR = persistent AR; SAR = seasonal AR; M = mild AR; M/S = moderate/severe AR; NA = not available; NS: nasal spray. 
* Assessed using the Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) questionnaire 
† Unknown working status 
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Table 3. Pooled analysis of the impact of rhinitis on work productivity: Estimates weighted for variance 
 
Study Type  
Absenteeism, %* Impaired presenteeism, %* Overall work productivity impairment, %* 
N studies 
(reference) 
N 
strata  
N 
participants 
Mean % 
(95% CI) 
N studies 
(reference) 
N 
strata 
N 
participants 
Mean % 
(95% CI) 
N studies 
(reference) 
N 
strata  
N 
participants 
Mean % 
(95% CI) 
All studies 
6 
(19, 25, 31, 
37, 39, 43) 
8 1666 2.3 (0; 7.9) 
8 
(17, 19, 25, 
31, 34, 37, 
39, 43) 
15 4563 32.5 (20.8; 44.1) 
11 
(17, 19, 25, 
31, 33-37, 
39, 43) 
22 6535 35.5 (25.2; 45.8) 
By study design: 
Observational 3 (19, 25, 43) 3 676 
2.8 
(0; 12.5) 
4 
(17, 19, 25, 
43) 
7 2803 23.9 (8.1;39.8) 
4 
(17, 19, 25, 
43) 
7 2802 25.0 (9.6; 40.4) 
Interventional 3 (31, 37, 39) 5 990 
2.2 
(0; 8.9) 
4 
(31, 34, 37, 
39) 
8 1760 42.6 (25.3; 59.9) 
7 
(31, 33-37, 
39) 
15 3733 44.0 (30.2; 57.9) 
By disease pattern: 
IAR/SAR 
4 
(31, 37, 39, 
43) 
6 1054 1.9 (0; 7.2) 
5 
(17, 31, 37, 
39, 43) 
9 2113 24.3 (12.6; 36.0) 
7 
(17, 31, 33, 
35, 37, 39, 
43) 
14 3523 30.2 (19.1; 41.4) 
PAR 1 (43) 1 NA NA 
3 
(17, 34, 43) 5 2015 
25.9 
(4.5; 47.2) 
4 
(17, 34, 36, 
43) 
7 2522 29.5 (9.3; 49.7) 
By disease severity: 
Mild AR 1 (43) 1 NA NA 
2 
(17, 43) 3 168 
13.8 
(0; 31.0) 
2 
(17, 43) 3 168 
14.2 
(0; 31.7) 
M/S AR 
5 
(25, 31, 37, 
39, 43) 
7 1347 2.2 (0; 7.9) 
7 
(17, 25, 31, 
34, 37, 39, 
43) 
12 4094 35.5 (22.0; 49.1) 
10 
(17, 25, 31, 
33-37, 39, 
43) 
19 6066 38.5 (27.0; 49.9) 
 
Legend: AR: allergic rhinitis; IAR: intermittent AR; NA: not appropriate; PAR: persistent AR; SAR: seasonal AR; M/S: moderate/severe AR. 
* Assessed using the Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) questionnaire 
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Table 4. Interventional studies: Impact of treatment on work productivity 
Reference Duration of AR 
Severity 
of AR 
Intervention 
group 
N 
participa
nts 
Impact on missed worktime 
(absenteeism)  
Impact on at-work productivity 
(presenteeism) Impact on overall work impairment 
Okubo, 2005 (31) SAR M/S Fexofenadine 79 NA Mean difference vs. baseline: 
• Treated = -5.6% 
• Placebo = +3.2% 
Mean difference vs. baseline: 
• Treated = -5.5% 
•  Placebo = +3.4% Placebo 89 
Bousquet, 2005 
(32) 
PAR M/S 
Levocetirizine 186 
Mean (95%CI) no. of missed work 
days/mo: 
• Treated = 0.2 (0.1-0.3) 
• Placebo = 0.4 (0.3-0.8) 
Mean (95% CI) work impairment, d/mo: 
• Treated = 0.7 (0.5-0.9) 
• Placebo =1.0 (0.8-1.3) 
Mean (95% CI) total work days lost, 
days per mo: 
• Treated = 0.9 (0.7-1.1) 
• Placebo =  1.49 (1.2-2.0) Placebo 196 
Fairchild 2007 (33) SAR M/S Olo 0.6% 293 NA NA Mean difference vs. baseline: 
• Olo 0,6% = -15.2% 
• Olo 0,4% : -13.0% 
• Placebo : -7.4% 
Olo 0.4% 303 
Placebo 297 
Bousquet, 2009 
(34) 
PAR : 
62% 
M/S : 
72% 
ARIA 339 Missed % work time:  
• ARIA group = 0 
• Free-choice group = 0 
Median (IQR) difference vs. baseline: 
• ARIA group = -20 (-35; 0)% 
• Free choice group = -10 (-30; 0)% 
Median (IQR) difference vs. baseline: 
• ARIA group = -20 (-40; 0)% 
• Free choice group = -10 (-30; 0)% Free-choice 342 
Bousquet, 2009 
(35) 
IAR M/S Desloratadine 262 NA NA Mean (SEM) difference vs. baseline: 
• Treated = -15.0 (2.8)% 
• Placebo = -5.7 (2.7)% Placebo 256 
Bousquet, 2010 
(36) 
PAR M/S Desloratadine 301 NA NA Mean (SEM) difference vs. baseline: 
• Treated = -15.9 (2.8)% 
• Placebo = -11.9 (2.7)% Placebo 261 
Mansfield, 2010 
(37) 
SAR M/S 
Levocetirizine 235 
Mean (SD) % work time missed at 
baseline and endpoint: 
• Treated = 4.5 (12.9); 1.2 (4.9) 
• Placebo = 3.5 (9.8); 2.3 (8.8)  
Mean (95% CI) % difference vs. 
placebo at endpoint: -1.4 (-2.6; -
0.2) 
Mean (SD) % work impairment at 
baseline and endpoint: 
• Treated = 51.8 (24.2); 37.8 (21.4)  
• Placebo = 49.0 (24.2); 40.9 (24.1)  
Mean (95% CI) % difference vs. placebo 
at endpoint: -4.6 (-8.3; -0.9) 
Mean (SD) % impairment in overall 
work productivity: 
• Treated = 52.9 (24.9); 38.2 (21.8) 
• Placebo = 49.9 (24.6); 40.9 (24.1)  
Mean (95% CI) % difference vs. 
placebo at endpoint: -4.4 (-8.2; -0.6) 
Placebo 233 
Meltzer, 2010 (38) PAR M/S Mometasone 20 Mean difference vs. baseline: 
• Treated = -2.2% 
• Placebo = +5.8% 
Mean difference vs. baseline: 
•Treated = -1.9% 
• Placebo = -0.1% 
NA 
Placebo 9 
Segall, 2010 (39) SAR M/S Levocetirizine 216 NA NA Adjusted mean difference between 
groups = -4.44% 
Placebo 227 
Legend: AR: allergic rhinitis; IAR = intermittent AR; PAR = persistent AR; SAR = seasonal AR; M/S = moderate/severe AR; NA: not available; Olo: Olopatadine nasal spray;  
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Table 5. Estimated costs of lost work productivity due to rhinitis 
Reference Study design Monetary unit (year) 
Average 
daily wage¥ 
Cost of 
absenteeism, 
mean per patient 
per yr 
Cost of 
presenteeism, 
mean per patient 
per yr 
Total cost of 
lost work 
productivity, 
mean per 
patient per yr 
Direct medical 
costs, mean 
per patient per 
yr 
Bousquet, 2005 (32) RCT of levocetirizine vs. placebo 
(6 mo), 5 EU countries; 2001-2002 
€ (2002) 106.76     
Levocetirizine group   153.96 589.20 (3.8)* 743.16 (3.4)† 218.16 
Placebo group   406.80 948.12 (2.3)* 1,354.92 (13.5)† 100.44 
Lamb, 2006 (18) Survey of 8,267 US employees 
(WPSI, 12 mo); 2001-2002 
US$ (2002) 274.00 182.99 409.56 (2.2)* 592.58 NA 
Kim, 2010 (24) Population survey based on 
Korean NHIC data; 2007 
US$ (2009) 82.51 11.53 NA NA 49.10 
Jantunen, 2014 (41) Nationwide questionnaire panel 
survey, Finland ; 2013 
€ (2011) 141.00 111.40 511.80 (4.6)* 623.20 NA  
Cardell, 2016 (42) Questionnaire-based survey of a 
random population sample, 
Sweden; 2014 
€ (2014) NA 78.0 672.8 (8.6)* 750.8 (3.6)† 210.3 
Colas, 2016 (43) Questionnaire-based survey of 498 
AR participants recruited in a 
national random sample of 101 
specialized clinics; follow-up of 12 
mo; Spain; 2009 
€ (2010) NA 90.19 1,682.71 (18.7)* 1,772.90 (3.2)† 553.80 
Legend: NHIC: National Health Insurance Corporation; RCT: randomized controlled trial; WPSI: Work Productivity Short Inventory questionnaire. 
* Cost of presenteeism/cost of absenteeism ratio 
† Total cost of lost productivity/direct medical cost ratio; 
¥ National average of workers’ daily wage used by investigators to calculate the cost components of AR. 
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